

APPRAISAL OF GUIDELINES FOR RESEARCH & EVALUATION Global Rating Scale

AGREE GRS



November 2017

COPYRIGHT AND REPRODUCTION

This document is the product of an international collaboration. It may be reproduced and used for educational purposes, quality assurance programmes and critical appraisal of guidelines. It may not be used for commercial purposes or product marketing. Approved non-English language versions of the AGREE GRS must be used where available. Offers of assistance in translation into other languages are welcome, provided they conform to the protocol set out by the AGREE research team.

DISCLAIMER

The AGREE GRS is a generic tool designed primarily to help guideline developers and users assess the methodological quality of clinical practice guidelines. The authors do not take responsibility for the improper use of the AGREE GRS.

SUGGESTED CITATION:

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham I, Grimshaw J, Hanna SE. The global rating scale complements the AGREE II in advancing the quality of practice guidelines. *J Clin Epidemiol* 2012;65(5):526-34; doi: 10.1016/j.jclinepi.2011.10.008

FUNDING:

The development of the AGREE II Instrument was funded by a grant from the Canadian Institutes of Health Research



For more information about the AGREE GRS, please contact the AGREE project office at agree@mcmaster.ca or visit the AGREE website at www.agreetrust.org

AGREE NEXT STEPS CONSORTIUM MEMBERSHIP

Dr. Melissa C. Brouwers
Principal Investigator, AGREE Next Steps Consortium
McMaster University, Hamilton, Ontario, Canada

Consortium Members:

Dr. GP. Browman, British Columbia Cancer Agency, British Columbia, Canada
Dr. JS. Burgers, Dutch Institute for Healthcare Improvement CBO, The Netherlands
Dr. F. Cluzeau, Global Health and Development Group, Imperial College London, London, UK
Dr. D. Davis, Association of American Medical Colleges, Washington DC, USA
Prof. G. Feder, University of Bristol, UK
Dr. B. Fervers, Cancer et Environnement, Centre Léon Bérard, France
Dr. I. Graham, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Dr. J. Grimshaw, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Dr. SE. Hanna, McMaster University, Hamilton, Ontario, Canada
Ms. ME. Kho, McMaster University, Hamilton, Ontario, Canada
Dr. P. Littlejohns, King's College London, London, UK
Ms. J Makarski, McMaster University, Hamilton, Ontario, Canada
Dr. L. Zitzelsberger, Quebec, Canada

AGREE GLOBAL RATING SCALE INSTRUCTIONS

I. Background

Clinical practice guidelines are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances (1), including health promotion, screening, diagnosis, and treatment. The 23-item AGREE II tool has become an international standard to direct the development, reporting and quality appraisal of guideline (2,3); however, user feedback indicates that there is need for a shorter appraisal tool as an alternative to the AGREE II when resources are sparse and application of a comprehensive tool is not feasible. A shorter tool was tested and published in 2012 as the Global Rating Scale (GRS) (4). Reliability testing indicates that the AGREE GRS was able to predict important outcome measures related to guideline adoption despite its lower sensitivity in detecting differences in guideline quality when compared to AGREE II (4). We continue to recommend the AGREE II as the primary tool to assess the methodological quality of clinical practice guidelines.

II. Preparing to Use the AGREE Global Rating Scale

i) Accompanying Guideline Documents

Before applying the AGREE GRS, users should first carefully read the guideline document and any relevant supporting documents published elsewhere.

ii) Number of Appraisers

We recommend that each guideline be assessed by a minimum of two appraisers to increase the reliability of the assessment.

III. AGREE Global Rating Scale Items

i) Items and considerations

The tool consists of four core items:

1. Process of development,
2. Presentation style,
3. Completeness of reporting
4. Clinical validity.

To guide the appraisal, a list of considerations is provided for each item.

ii) Rating Scale

The four AGREE GRS items are rated on the following 7-point scale:

Lowest Quality			Highest Quality			
1	2	3	4	5	6	7

Score of 1 (*Lowest Quality*). A score of 1 should be given when there is no information that is relevant to the AGREE GRS item, if the concept is very poorly presented in the guideline, or if the authors explicitly state that the criteria were not met.

Score of 7 (*Highest Quality*). A score of 7 should be given if the quality of reporting and presentation is exceptional and if the considerations have been fully met.

Scores between 2 and 6. A score between 2 and 6 is assigned when the reporting of the AGREE GRS item does not meet the full considerations. A score is assigned depending on the completeness and quality of reporting and presentation.

It is important to note that item ratings require a level of judgment. The considerations are provided to guide, not to replace, these judgments. Thus, none of the AGREE GRS items provide explicit expectations for each of the 7 points on the scale.

IV. Overall Assessment

Upon completing the four items, AGREE GRS users are asked to provide three overall assessments of the guideline. The overall quality assessment requires the user to make a judgment as to the quality of the guideline (1=lowest quality, 7=highest quality), taking into account the criteria used in the assessment of the four core items. Users are also asked whether they would recommend the guideline for use in practice and whether they would make use of a guideline of that quality in their own professional decisions (1=strongly disagree, 7=strongly agree).

References

1. Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. *BMJ*. 1999;318(7182):527-30.
2. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna SE, Littlejohns P, Makarski J, Zitzelsberger L, for the AGREE Next Steps Consortium. AGREE II: Advancing guideline development, reporting and evaluation in healthcare. *CMAJ* 2010;182(18):E839-42.
3. Makarski J, Brouwers MC. The AGREE Enterprise: a decade of advancing clinical practice guidelines. *Implement Sci*. 2014 Aug 15;9(1):103.
4. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, Graham ID, Grimshaw J, Hanna SE, Littlejohns P, Makarski J, Zitzelsberg L, for the AGREE Next Steps Consortium. The Global Rating Scale complements the AGREE II in advancing the quality of practice guidelines. *J Clin Epidemiol* 2012;65:526-34.

AGREE GLOBAL RATING SCALE

PROCESS OF DEVELOPMENT

1. Rate the overall quality of the guideline development methods.

Consider:

- Were the appropriate stakeholders involved in the development of the guideline?
- Was the evidentiary base developed systematically?
- Were recommendations consistent with the literature?



Were the appropriate stakeholders involved in the development of the guideline?

-Ja, er wordt verwezen naar verpleegkundigen in Queensland als doelgroep.

Was the evidentiary base developed systematically?

-Er worden meerdere 'references' onderzoeken, systematic reviews benoemd als bewijs.

Were recommendations consistent with the literature?

Ja, de bronnen komen overeen met de aanbevelingen.

PRESENTATION STYLE

2. Rate the overall quality of the guideline presentation.

Consider:

- Was the guideline well organized?
- Were the recommendations easy to find?



Was the guideline well organized?

-Ja, het begint met een goede introductie, goede kopjes en een bronnenlijst. Inhoudsopgave is ook goed.

Were the recommendations easy to find?

-Ja, alles is goed aangegeven met kopjes en daarbij vaak een tabel met verduidelijking.

COMPLETENESS OF REPORTING

3. Rate the completeness of reporting.

Consider:

- Was the guideline development process transparent and reproducible?
- How complete was the information to inform decision-making?

Lowest Quality					Highest Quality	
1	2	3	4	5	<input checked="" type="radio"/>	7

Was the guideline development process transparent and reproducible?

Ja, het is algemeen en kan op alle vroeg jong geboren baby's worden toegepast.

How complete was the information to inform decision-making?

Alle informatie wordt goed toegelicht.

CLINICAL VALIDITY

4. Rate the overall quality of the guideline recommendations.

Consider:

- Are the recommendations clinically sound?
- Are the recommendations appropriate for the intended patients?

Lowest Quality					Highest Quality	
1	2	3	4	5	6	<input checked="" type="radio"/>

Are the recommendations clinically sound?

Ja, het is gebaseerd op meerdere onderzoeken.

Are the recommendations appropriate for the intended patients?

Ja, want er zal een positief effect zijn voor de baby.

OVERALL ASSESSMENT

1. Rate the overall quality of this guideline.



2. I would recommend this guideline for use in practice.



3. I would make use of a guideline of this quality in my professional decisions.



-Geen verdere toelichting hiervoor nodig.